Finadyne® 50 mg/ml Solution for Injection
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic activities.
Presentation
Solution for injection
Active ingredients
Each ml contains:
Active substance:
50 mg Flunixin equivalent to 83 mg Flunixin meglumine.
Target species
Cattle, horses and pigs
Indications for use
In Cattle:
Adjunctive therapy in the treatment of bovine respiratory diseases, endotoxemia and acute mastitis.
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain associated with dehorning in calves of less than 9 weeks.
In Horses:
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Alleviation of visceral pain associated with colic.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical conditions or diseases that result in impaired blood circulation in the gastrointestinal tract.
Reduction of pyrexia
In Pigs:
Adjunctive therapy in the treatment of swine respiratory disease.
Adjunctive treatment of postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome in sows.
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain following castration and tail docking in sucking piglets.
Withdrawal periods
Animals must not be slaughtered for human consumption during treatment.
Cattle:
Meat and offal: 4 days (intravenous use)
31 days (intramuscular use)
Milk: 24 hours (intravenous use)
36 hours (intramuscular use)
Pigs:
Meat and offal: 24 days (intramuscular)
Horses:
Meat and offal: 5 days (intravenous use)
Milk: Not authorised for use in animals producing milk for human consumption
Milk for human consumption must not be taken during treatment.
Packaging
1 x 50 ml vial
6 x 50 ml vial
10 x 50 ml vial
1 x 100 ml vial
10 x 100 ml vial
1 x 250 ml vial
6 x 250 ml vial
Not all pack sizes may be marketed.
Legal category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: January 2026